Therapy News and Research

RSS

Allergy shots are cost-effective and deliver relief in weeks

Allergy shots, an age-old treatment for allergy sufferers, are getting a shot in the arm from new research. This proven therapy saves money; accelerated schedules deliver relief in weeks, rather than months; and alternative methods are on the horizon, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology in Boston, Nov 3-8.

3 Nov 2011

Clinical-grade viral vector can cure choroideremia

Researchers at Ohio State University Medical Center and Nationwide Children's Hospital have developed a viral vector designed to deliver a gene into the eyes of people born with an inherited, progressive form of blindness that affects mainly males.

3 Nov 2011

FEIBA drug safe and effective for patients with hemophilia A

An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place.

3 Nov 2011

MSCs can be reprogrammed to have enhanced survival and therapeutic efficacy

Chinese stem cell scientists have published new research that improves the survival and effectiveness of transplanted stem cells. The research led by Dr Hsiao Chang Chan, from the Chinese University of Hong Kong, is published in Stem Cells.

3 Nov 2011

Combination of Mediterranean diet, physical activity can help improve symptoms of OSAS

Eating a Mediterranean diet combined with physical activity can help to improve some of the symptoms of sleep apnoea, according to new research.

3 Nov 2011

Edwards Lifescience receives FDA approval for Sapien Transcatheter Heart Valve

The U.S. Food and Drug Administration today approved the first artificial heart valve that can replace an aortic heart valve damaged by senile aortic valve stenosis without open-heart surgery.

3 Nov 2011

IP-K and Sanofi form new HBV research collaboration

One of the most common and serious infectious diseases, Hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea (IP-K), and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea. The goal is to develop and validate a high throughput assay to screen IP-K's chemical libraries for novel compounds that can be developed as new drugs.

3 Nov 2011

DexCom signs research and development agreement with Roche

Roche Diagnostics U.S., with its business unit Roche Diabetes Care, a leader in blood glucose monitoring and insulin delivery systems, and DexCom, Inc., a leader in continuous glucose monitoring systems, announced today that they have signed a research and development agreement.

From Roche Sequencing and Life Science 3 Nov 2011

Final results from Medivir's TMC435 phase IIb study on genotype-1 hepatitis C

Medivir AB, a research-based speciality pharmaceutical company focused on infectious diseases, today announces final results from the ASPIRE study.

3 Nov 2011

ADHD drugs don’t raise risk for heart attacks or stroke: Study

Drugs known as stimulants, that are used to treat attention deficit hyperactivity disorder do not increase the risk of heart attacks, strokes or sudden death, U.S. researchers said on Monday. This study finding should reassure millions of parents whose children take the drugs.

2 Nov 2011

AVEO third quarter net loss increases to $23.8 million

AVEO Pharmaceuticals, Inc. today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

2 Nov 2011

First Edition: November 2, 2011

In today's headlines, reports about Tuesday's super committee hearing and the message communicated by bipartisan budget hawks to the panel -- raise revenue and revamp health programs.

2 Nov 2011

Radiation therapy prior to HCT improves outcomes in older patients with hematologic malignancies

Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic hematopoietic cell transplantation had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies, according to a study in the November 2 issue of JAMA.

2 Nov 2011

DJO Global third quarter net sales increase 12.7% to $263.1 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the third quarter of fiscal 2011, ended October 1, 2011.

2 Nov 2011

Inhibiting Notch signalling makes hormone-receptor positive cells dependent on estrogen

Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells - knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor takeover by more dangerous, receptor-negative cells.

2 Nov 2011

PSTC, FNIH Biomarkers Consortium launch clinical study to improve detection of kidney injury

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced today the launch of a two-year clinical study aiming to advance the acceptance of new biomarkers designed to detect drug-induced kidney injury in clinical trials.

2 Nov 2011

Age is no longer a barrier to allogeneic stem cell transplantation

Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That's the conclusion of the first study summarizing long-term outcomes from a series of prospective clinical trials of patients age 60 and over who were treated with the mini-transplant, a "kinder, gentler" form of allogeneic (donor cell) stem cell transplantation developed at Fred Hutchinson Cancer Research Center.

2 Nov 2011

Prostate cancer patients with bone metastases benefit from repeated 188Re-HEDP therapy

For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.

2 Nov 2011

Johns Hopkins breast cancer researcher wins BioMaryland LIFE Prize

A Johns Hopkins breast cancer researcher is the recipient of a $50,000 award designed to encourage rapid translation of her basic research on biomarkers into a commercially available test that could predict the best treatment options for some women with breast cancer.

2 Nov 2011

Birth control shot may impair a person's memory

The birth control shot Depo Provera offers a convenient alternative for women who don't want to remember to take a daily pill. Ironically, research from Arizona State University has shown the shot actually may impair a person's memory.

2 Nov 2011